

Chronic Traumatic Encephalopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/CC510366BC97EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CC510366BC97EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Traumatic Encephalopathy Understanding

Chronic Traumatic Encephalopathy: Overview

Chronic traumatic encephalopathy is characterized by progressive neurodegeneration of brain due to repetitive traumatic brain injuries, including concussions as well as repeated blow to the head. Athletes who play contact sports such as boxing, football, and military veterans are at greater risk for CTE owing to their increased chances of enduring frequent and repeated blows to the head.

"Chronic Traumatic Encephalopathy- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the

indication. A detailed picture of the Chronic Traumatic Encephalopathy pipeline landscape is provided which includes the disease overview and Chronic Traumatic Encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Chronic Traumatic Encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Traumatic Encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Traumatic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Traumatic Encephalopathy.

Chronic Traumatic Encephalopathy Emerging Drugs Chapters

This segment of the chronic traumatic encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Traumatic Encephalopathy Emerging Drugs

N-acetylcysteine Amide (NACA): Brighton Biotech, Inc.

Brighton Biotech's lead drug candidate, N-acetylcysteine Amide, is a small anti-oxidant molecule in development for the treatment of CTE. It is a potential drug to attenuate the destructive effects of oxidation while brain injuries.

Further product details are provided in the report.....

Chronic Traumatic Encephalopathy: Therapeutic Assessment

This segment of the report provides insights about the different chronic traumatic encephalopathy drugs segregated based on following parameters that define the scope

of the report, such as:

Major Players in Chronic Traumatic Encephalopathy

There are approx. 3+ key companies which are developing the therapies for chronic traumatic encephalopathy. The companies which have their chronic traumatic encephalopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Brighton Biotech, Inc. and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic traumatic encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Traumatic Encephalopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses chronic traumatic encephalopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging chronic traumatic encephalopathy drugs.

Chronic Traumatic Encephalopathy Report Insights

Chronic Traumatic Encephalopathy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Traumatic Encephalopathy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing chronic traumatic encephalopathy drugs?

How many chronic traumatic encephalopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of chronic traumatic encephalopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the chronic traumatic encephalopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for chronic traumatic encephalopathy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Brighton Biotech Inc.

Tetra Therapeutics

Key Products

N-acetylcysteine Amide (NACA)

PDE4B inhibitor

Contents

Introduction

Executive Summary

Chronic Traumatic Encephalopathy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chronic Traumatic Encephalopathy – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Chronic Traumatic Encephalopathy companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Chronic Traumatic Encephalopathy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Pre-clinical and Discovery Stage Products

Comparative Analysis

N-acetylcysteine Amide: Brighton Biotech Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Chronic Traumatic Encephalopathy Key Companies

Chronic Traumatic Encephalopathy Key Products

Chronic Traumatic Encephalopathy- Unmet Needs

Chronic Traumatic Encephalopathy- Market Drivers and Barriers

Chronic Traumatic Encephalopathy- Future Perspectives and Conclusion
Chronic Traumatic Encephalopathy Analyst Views
Chronic Traumatic Encephalopathy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Chronic Traumatic Encephalopathy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Chronic Traumatic Encephalopathy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Chronic Traumatic Encephalopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CC510366BC97EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC510366BC97EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970